Oral Biologics Market, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC), Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023

Code : CMI989

Pages :197

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenges And Opportunities

Global Oral Biologics Market– Drivers

Increasing prevalence of diabetes: The increasing prevalence of diabetes worldwide is expected to drive the market growth over the forecast period. For instance, according to an article published by the WHO (World Health Organization) in April 2023, diabetes cases increased from 108 million in 1980 to 422 million in 2014. Prevalence has risen faster in low- and middle-income countries than in high-income countries. Furthermore, according to the same source, diabetes caused a 3% increase in age-standardized death rates between 2000 and 2019. Diabetes-related mortality increased by 13% in lower-middle-income countries.
Increasing research and development activities: Increasing research and development activities regarding oral biologics by market players is also expected to boost the global oral biologics market over the forecast period. For instance, in February 2023, Intralytix, Inc., a biotechnology company, initiated study on the safety and efficacy of oral biologic VRELysin in the treatment of Vancomycin-resistant enterococcal colonization. The study is in phase 2 of clinical trila and is expected to be completed in March 2025.

Global Oral Biologics Market: Restraint

Product recalls by the manufacturers

Voluntary recalls of oral biologics such as hormones are expected to hinder market growth over the forecast period. For instance, in May 2020, Pfizer, a U.S.-based biotechnology company, announced a voluntary recall of Duavee, an estrogen-based menopause hormone therapy, to ensure product stability throughout its shelf life.

The manufacturing companies are expected to standardize the manufacturing and production processes of the drugs to ensure product quality and stability throughout their shelf life.

Global Oral Biologics Market- Cross Sectional Analysis:

In drug class, hormone segment is expected to dominate the market in the North America region, and this is attributable to the increasing product approvals from regulatory authorities. For instance, in December 2020, Myovant Sciences, a biopharmaceutical company, announced that the U.S. FDA approved Orgovyx (relugolix), the first oral hormone therapy for treating advanced prostate cancer.